85-1794-31　PILRA, Recombinant, Human, aa20-196 (FDF03, PILR-alpha, Paired Immunoglobulin-like Type 2 Receptor-alpha) 50ug　145827

特徴

• PILR­alpha (paired immunoglobulin­like type 2 receptor­alpha; also FDF03) is one of two members that belong to a small family of immunoregulatory Ig­superfamily receptors (1­4). It is a counterpart to PILR­beta, and likely gave rise to the PILR­beta gene through duplication and rearrangement (1). The PILRs represent one of many pairs of Ig­like domain­containing receptors that participate in immune regulation. PILR­alpha and ­beta should not be confused with the similarly named PIRs (also paired immunoglobulin­like receptors ), or the functionally­related SIRP and ILT/LILR/CD85/LIR family of receptors (2). While PIRs, ILTs and SIRPs contain three to six Ig­like domains in their extracellular region, PILR­alpha and ­beta show only one Ig­like region in their extracellular domain (ECD) (1­5). Human PILR­alpha is a monomeric, 55kD, 294 amino acid (aa) type I transmembrane (TM) glycoprotein (3­5). It contains a 178 aa ECD (aa 20­197), a 21 aa TM segment, and a long, 85 aa cytoplasmic region (aa 219­303). The ECD shows one V­type Ig­like domain between aa 32­150, while the cytoplasmic region contains two ITIMs (immunoreceptor Tyr­based inhibitory motifs) between aa 267­272 and 296­301. Given that ITIMs are known to interact with phosphatases such as PTPN6 and PTPN11, the presence of these motifs make mouse PILR­alpha an inhibitory receptor. Three potential isoforms for human PILR­alpha have been reported. The first contains a 24 aa substitution for aa 152­303, a second possesses a 36 aa substitution for aa 264­303, and a third shows a deletion of aa 152­224 (6). The human PILR­alpha ECD shares 43% aa sequence identity with mouse PILR­alpha ECD, and 82% aa sequence identity with the ECD of human PILR­beta (3, 4)
• PILR­alpha is expressed by neutrophils, macrophages, monocytes, mast cells, APCs, microglia, neurons, cardiac muscle and renal proximal plus pancreatic duct eipthelium (4, 7, 8). It has multiple binding partners, including CD99 (4, 9), glycoprotein B/gB of HSV­1 (7), PANP (PILR­associated neural protein) (8) and NPDC1 plus collectin­12 (10). Although PILR­alpha and ­beta are related through gene duplication and highly similar in their ECD aa sequence, they do not necessarily share the same ligands (or binding partners), as PILR­beta fails to bind to gB and PANP (8, 10). Notably, PILR­alpha binding appears to be dependent upon the presence of a poorly­defined peptide sequence coupled to a sialylated, O­linked carbohydrate motif (5, 9­12). It is unclear what function(s) can be attributed to PILR­alpha. One possibility suggests that in the early stage of an immune response, PILR­beta predominates over PILR­alpha on the APC surface. Ligation of PILR­beta by CD99 induces IL­12 production and immune cell activation. But this ligation also up­regulates PILR­alpha expression, and subsequent CD99:PILR­alpha engagement now promotes IL­27 production, with a concomitant increase in T cell IL­10 production, and a down­regulation of the inflammatory response (10).
• Source:Recombinant protein corresponding to aa20-196, Gln20-Thr196, from human PILR-alpha, fused to 6xHis-Tag at C-terminal, NS0-derived.
• Molecular Weight:~33-40kD
• Endotoxin:<0.10EU/1ug (LAL method)
• Biological Activity:Measured by its binding ability in a functional ELISA. When recombinant human PANP Fc Chimera is immobilized at 5ug/ml (100ul/well), the concentration of Recombinant Human PILR-alpha that produces 50% optimal binding response is approximately 0.4-2ug/ml.
• Storage and Stability:Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute in sterile PBS. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Reconstituted product is stable for 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.